Astrazeneca (AZN)

 

AZN Share PerformanceMore

52 week high5,520.0 22/06/17
52 week low3,996.0 06/12/16
52 week change 635.0 (14.63%)
4 week volume45,487,111 25/10/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Broker Forecast - HSBC issues a broker note on AstraZeneca PLC

HSBC today reaffirms its reduce investment rating on AstraZeneca PLC (LON:AZN) and raised its price target to 4380p (f...

AZ Fasenra gets FDA approval for severe asthma

AstraZeneca and its global biologics research and development arm, MedImmune, have announced that the US Food and D...

AZ Fasenra receives FDA approval for severe asthma

RNS Number: 5114W AstraZeneca PLC 14 November 2017 This announcement contains inside information 14 November 2017 22:45 GMT FASENRA (BENRALIZUMAB) RECEIVES US FDA APPROVAL FOR SEVERE EOSINOPHILIC ASTHMA Fasenra distinctively targets and rapidly depletes eosinophils and is the first respiratory biologic with an 8-week maint...

AstraZeneca receives positive EU CHMP opinion for asthma treatment

AstraZeneca has confirmed that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicin...

BENRALIZUMAB POSITIVE CHMP IN EOSINOPHILIC ASTHMA

RNS Number: 1876W AstraZeneca PLC 10 November 2017 This announcement contains inside information 10 November 2017 11:35GMT BENRALIZUMAB RECEIVES POSITIVE EU CHMP OPINION FOR SEVERE, UNCONTROLLED EOSINOPHILIC ASTHMA Benralizumab uniquely targets and rapidly depletes eosinophils and is the first respiratory biologic w...

FTSE 100 dips after weak Wall Street trading

The FTSE 100 edged down 2.81 points to 7,527.09 on Thursday morning after trading on Wall Street was held back by conce...

AstraZeneca operating profits rise

AstraZeneca's reported operating profits rose to $1,149m in the third quarter - up 12% on an actual basis and 9% at constant...

AZN: Year-To-Date and Q3 2017 Results Announcement

RNS Number: 9871V AstraZeneca PLC 09 November 2017 AstraZeneca PLC 9 November 2017 07:00 Year-To-Date and Q3 2017 Results An improved sales performance as the pipeline-driven transformation gathered pace Financial Summary YTD 2017 Q3 2017 $m % change $m % change Actual CER 1 Actual CER Total Revenue 16,688 (4) (3) 6,232 9 10 Product Sales 14...

Latest discussion posts More

Users' HoldingsMore

Users who hold Astrazeneca also hold..
GLAXOSMITHKLINE47%
BP35%
VODAFONE GRP.35%
NATIONAL GRID35%
LLOYDS GRP.33%

Codes & Symbols

ISINGB0009895292
SymbolsAZN, LSE:AZN, AZN.L, AZN:LN, LON:AZN, XLON:AZN

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account